ArticleInternational journal of clinical and experimental pathology2013
Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.
Article in International journal of clinical and experimental pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Navigating Preclinical Models and Medications for Peripheral Neuropathy: A Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Identification and verification of m7G-Related genes as biomarkers for prognosis of sarcoma.Frontiers in genetics · 2023Article
- Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.Cancer drug resistance (Alhambra, Calif.) · 2023Article
- Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes.Nature communications · 2022Article
- Differentially expressed genes related to lymph node metastasis in advanced laryngeal squamous cell cancers.Oncology letters · 2022Article
- Exploration of a predictive model based on genes associated with fatty acid metabolism and clinical treatment for head and neck squamous cell carcinoma.Journal of clinical laboratory analysis · 2022Article
- Detecting Blood Methylation Signatures in Response to Childhood Cancer Radiotherapy via Machine Learning Methods.Biology · 2022Article
- AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Down-regulation of MSMO1 promotes the development and progression of pancreatic cancer.Journal of Cancer · 2022Article
- Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.Molecular biology reports · 2021Article
- In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses.International journal of molecular sciences · 2021Article
- Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers.Frontiers in cell and developmental biology · 2021Review
- Eosinophil microRNAs Play a Regulatory Role in Allergic Diseases Included in the Atopic March.International journal of molecular sciences · 2020Article
- Optimization and Evaluation of Poly(lactide-Pharmaceutics · 2020Article
- Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells.Molecular biology reports · 2020Article
- Expression of miR-1304 in patients with esophageal carcinoma and risk factors for recurrence.World journal of gastroenterology · 2020Article
- Effects of Chemotherapy on Serum Lipids in Chinese Postoperative Breast Cancer Patients.Cancer management and research · 2020Article
- Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM.Molecular therapy oncolytics · 2019Article
- MiR-1284 suppresses gastric cancer progression by targeting EIF4A1.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel has been proved to be active in treatment and larynx preservation of HNSCC, however, the fact that about 20-40% patients do not respond to paclitaxel makes it urgent to figure out the biomarkers for paclitaxel-based treatment in Hypopharynx cancer (HPC) patients to improve the therapy effect. In this work, Fadu cells, treated or untreated with low dose of paclitaxel for 24 h, were applied to DNA microarray chips. The differential expression in mRNAs and miRs was analyzed and the network between expression-altered mRNAs and miRs was constructed. Differentially expressed genes were mainly enriched in superpathway of cholesterol biosynthesis (ACAT2, MSMO1, LSS, FDFT1 and FDPS etc.), complement system (C3, C1R, C1S, CFR and CFB etc.), interferon signaling (IFIT1, IFIT3, IFITM1 and MX1 etc.), mTOR signaling (MRAS, PRKAA2, PLD1, RND3 and EIF4A1 etc.) and IGF1 signaling (MRAS, IGFBP7, JUN and FOS etc.), most of these pathways are implicated in tumorigenesis or chemotherapy resistance. The first three pathways were predicted to be suppressed, while the last two pathways were predicted to be induced by paclitaxel, suggesting the combination therapy with mTOR inhibition and paclitaxel might be better than single one. The dramatically expression-altered miRs were miR-112, miR-7, miR-1304, miR-222*, miR-29b-1* (these five miRs were upregulated) and miR-210 (downregulated). The 26 putative target genes mediated by the 6 miRs were figured out and the miR-gene network was constructed. Furthermore, immunoblotting assay showed that ERK signaling in Fadu cells was active by low dose of paclitaxel but repressed by high dose of paclitaxel. Collectively, our data would provide potential biomarkers and therapeutic targets for paclitaxel-based therapy in HPC patients.
Indexed as
Identifiers
24294361PMC3843255W196558497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.